EA200900010A1 - Замещенные 8-[6-амино-3-пиридил]ксантины - Google Patents

Замещенные 8-[6-амино-3-пиридил]ксантины

Info

Publication number
EA200900010A1
EA200900010A1 EA200900010A EA200900010A EA200900010A1 EA 200900010 A1 EA200900010 A1 EA 200900010A1 EA 200900010 A EA200900010 A EA 200900010A EA 200900010 A EA200900010 A EA 200900010A EA 200900010 A1 EA200900010 A1 EA 200900010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
substituted
xanthes
pyridil
compositions
Prior art date
Application number
EA200900010A
Other languages
English (en)
Other versions
EA016791B1 (ru
Inventor
Гуокван Ванг
Роберт Д. Томпсон
Джейсон М. Ригер
Original Assignee
ПиДжиИксХЕЛТ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиДжиИксХЕЛТ, ЭлЭлСи filed Critical ПиДжиИксХЕЛТ, ЭлЭлСи
Priority claimed from PCT/US2007/013849 external-priority patent/WO2007149277A2/en
Publication of EA200900010A1 publication Critical patent/EA200900010A1/ru
Publication of EA016791B1 publication Critical patent/EA016791B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены замещенные 8-[6-амино-3-пиридил]ксантины и фармацевтические композиции, которые являются селективными антагонистами А2В аденозиновых рецепторов (АР). Эти соединения и композиции полезны в качестве фармацевтических агентов.
EA200900010A 2006-06-16 2007-06-13 Замещенные 8-[6-амино-3-пиридил]ксантины EA016791B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US80556406P 2006-06-22 2006-06-22
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines
PCT/US2007/013849 WO2007149277A2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (2)

Publication Number Publication Date
EA200900010A1 true EA200900010A1 (ru) 2009-10-30
EA016791B1 EA016791B1 (ru) 2012-07-30

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900010A EA016791B1 (ru) 2006-06-16 2007-06-13 Замещенные 8-[6-амино-3-пиридил]ксантины

Country Status (18)

Country Link
US (2) US7884100B2 (ru)
EP (1) EP2029143B1 (ru)
JP (1) JP5417558B2 (ru)
KR (1) KR101413404B1 (ru)
CN (1) CN103145712A (ru)
AU (1) AU2007261568B2 (ru)
BR (1) BRPI0712001B8 (ru)
CA (1) CA2655598C (ru)
DK (1) DK2029143T3 (ru)
EA (1) EA016791B1 (ru)
ES (1) ES2548437T3 (ru)
HU (1) HUE026457T2 (ru)
IL (1) IL195916A (ru)
MX (1) MX2008015954A (ru)
MY (1) MY152178A (ru)
NZ (1) NZ597222A (ru)
PL (1) PL2029143T3 (ru)
PT (1) PT2029143E (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PL1658291T3 (pl) * 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA3218963A1 (en) 2021-05-18 2022-11-24 Robert Thompson Cyclic amide-containing pyridyl xanthines as a2b antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1255550A2 (en) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
BR0302965A (pt) * 2002-02-01 2005-02-09 King Pharmaceuticals Res & Dev Composto e método de tratar doenças mediadas por receptores de adenosina a2b
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
PL1658291T3 (pl) * 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
MX2007002437A (es) * 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
WO2006028840A2 (en) 2004-09-03 2006-03-16 United States Postal Service Methods and systems for providing an enterprise supply management portal
NZ589657A (en) * 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
NZ571324A (en) * 2006-03-17 2011-07-29 Gilead Palo Alto Inc Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists
WO2007149115A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist

Also Published As

Publication number Publication date
CA2655598C (en) 2014-10-28
CN103145712A (zh) 2013-06-12
HUE026457T2 (en) 2016-05-30
AU2007261568B2 (en) 2013-05-16
ES2548437T3 (es) 2015-10-16
PL2029143T3 (pl) 2015-12-31
BRPI0712001B8 (pt) 2021-05-25
EP2029143A4 (en) 2009-07-15
EA016791B1 (ru) 2012-07-30
JP5417558B2 (ja) 2014-02-19
US8258142B2 (en) 2012-09-04
KR101413404B1 (ko) 2014-06-27
KR20090029268A (ko) 2009-03-20
CA2655598A1 (en) 2007-12-27
AU2007261568A1 (en) 2007-12-27
US7884100B2 (en) 2011-02-08
BRPI0712001B1 (pt) 2020-04-07
US20080004292A1 (en) 2008-01-03
IL195916A0 (en) 2009-09-01
MY152178A (en) 2014-08-15
US20110082139A1 (en) 2011-04-07
DK2029143T3 (en) 2015-09-21
BRPI0712001A2 (pt) 2012-01-10
NZ597222A (en) 2013-06-28
EP2029143A2 (en) 2009-03-04
JP2010500284A (ja) 2010-01-07
EP2029143B1 (en) 2015-07-08
IL195916A (en) 2015-06-30
MX2008015954A (es) 2009-03-06
PT2029143E (pt) 2015-10-20

Similar Documents

Publication Publication Date Title
WO2006091898A3 (en) Pyrazolyl substituted xanthines
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
ATE481409T1 (de) Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
CU20070156A7 (es) Compuestos de quinolina heteroaromaticos y su uso como inhibidores de pde10
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
BRPI0716936A2 (pt) derivados de adenosina como antigonistas de receptor de a2a
WO2010036407A3 (en) Antiviral nucleoside analogs
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
TW200740814A (en) Compounds
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
DK2064348T3 (da) Profilering af receptorfamilie
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила
UA100035C2 (en) Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title